Heart imaging study for ATTR amyloidosis patients
Part of Brain & nervous system, Genetic & congenital, Hormones & metabolism clinical trials.
This study uses heart imaging to track disease progression in people with ATTR cardiac amyloidosis who are about to start tafamidis treatment. It aims to understand how the disease changes over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with cardiac ATTR amyloidosis based on current medical guidelines.
- You are about to start treatment with tafamidis at University Hospital Zurich.
- You are not currently taking any other disease-modifying therapies like patisiran.
- You do not have an ongoing fast or irregular heartbeat (supraventricular arrhythmia) that hasn't been controlled.
- You do not have a ventricular pacemaker.
- You have not had a heart attack affecting the septum (wall between heart chambers).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows patients with a specific type of heart amyloidosis (wild-type ATTR) who are taking or could start the drug tafamidis. It aims to learn more about how the condition and treatment affect people over time.
This trial studies whether ultrasound therapy can help people with amyloidosis that affects the heart. It’s aimed at improving heart-related outcomes in AL or transthyretin (ATTR) cardiac amyloidosis.
This study looks at people who carry certain TTR gene variants, which can cause a specific type of heart amyloid buildup. It also includes people with symptoms, to understand how the condition develops and how it may be monitored.
This study uses special imaging tracers to see how much they build up in the heart in people with cardiac transthyretin (ATTR) amyloidosis. It may help researchers better measure disease activity and understand who benefits from treatments like tafamidis.
This trial uses special heart imaging to better measure how amyloid deposits affect the heart in people with certain diagnoses. The goal is to understand which imaging signals match your disease and to see if this approach could help guide care.
This study looks at how a heart medication (tafamidis) affects amyloid protein levels in the blood over time. It may help doctors understand how well the treatment works for people with a specific type of heart disease caused by amyloid buildup (ATTR-CM).
Hear when a new Amyloidosis Cardiac trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.